Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 1,680,000 shares, a decline of 8.2% from the March 15th total of 1,830,000 shares. Based on an average trading volume of 150,300 shares, the days-to-cover ratio is currently 11.2 days. Approximately 5.3% of the shares of the company are short sold.

Monte Rosa Therapeutics Stock Down 7.8 %

Shares of NASDAQ:GLUE traded down $0.51 during trading on Tuesday, reaching $6.06. 125,484 shares of the company’s stock traded hands, compared to its average volume of 150,186. Monte Rosa Therapeutics has a fifty-two week low of $2.44 and a fifty-two week high of $8.84. The company has a 50-day simple moving average of $6.36 and a 200-day simple moving average of $5.12. The firm has a market cap of $303.91 million, a PE ratio of -2.30 and a beta of 1.45.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01). On average, equities research analysts forecast that Monte Rosa Therapeutics will post -2.25 EPS for the current year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of large investors have recently added to or reduced their stakes in GLUE. Swiss National Bank raised its position in shares of Monte Rosa Therapeutics by 7.4% during the 1st quarter. Swiss National Bank now owns 27,500 shares of the company’s stock worth $386,000 after purchasing an additional 1,900 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of Monte Rosa Therapeutics in the first quarter valued at approximately $144,000. JPMorgan Chase & Co. boosted its stake in shares of Monte Rosa Therapeutics by 92.8% in the first quarter. JPMorgan Chase & Co. now owns 22,512 shares of the company’s stock worth $316,000 after acquiring an additional 10,838 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Monte Rosa Therapeutics by 132.4% during the first quarter. Bank of New York Mellon Corp now owns 74,319 shares of the company’s stock worth $1,042,000 after purchasing an additional 42,340 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in Monte Rosa Therapeutics in the 1st quarter valued at $255,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wedbush started coverage on shares of Monte Rosa Therapeutics in a research note on Thursday, February 15th. They set an “outperform” rating and a $11.00 price objective on the stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.